Walleye Capital
AVDL

Walleye Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Walleye Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,887
Closed -$28.8K – 4557
2025
Q3 		$28.8K Sell
1,887
-69,984
-97% -$911K ﹤0.01% 4149
2025
Q2 		$636K Buy
71,871
+71,449
+16,931% +$628K ﹤0.01% 2432
2025
Q1 		$3.3K Buy
+422
New +$3.53K ﹤0.01% 4118
2024
Q3 		– Sell
-766
Closed -$10.8K – 5271
2024
Q2 		$10.8K Sell
766
-9,019
-92% -$147K ﹤0.01% 5217
2024
Q1 		$165K Buy
+9,785
New +$146K ﹤0.01% 4092
2019
Q4 		– Sell
-30,758
Closed -$128K – 1770
2019
Q3 		$128K Buy
+30,758
New +$77K 0.01% 1358

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's AVDL Position: Q4 2025 in Review

Walleye Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 1,887 shares — an estimated $28.8K sold.

Walleye Capital first reported a position in AVDL in Q3 2019 and held it in 6 quarters. The position peaked at $636K in Q2 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Walleye Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 1,887 Avadel Pharmaceuticals shares in Q4 2025, an estimated $28.8K.
  • Walleye Capital first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 6 quarters.
  • Walleye Capital's Avadel Pharmaceuticals position peaked at $636K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.